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TO THE EDITORApoptosis,
A Double-Edge Sword!We read with interest the paper by Weil et al. (1),
which has also been editorialized by Jaffe (2) and
Amgalan et al. (3). In this paper, a single brief episode
of 10-min myocardial ischemia and 24-h reperfusion
was shown to increase serum cardiac troponin I, with
transient regional apoptosis of single dispersed car-
diomyocytes being proposed as a potential mecha-
nism. We would like to put the focus on the link
between such short periods of ischemia/reperfusion,
the apoptotic process, and cardioprotection.
Ischemic pre-conditioning (IPC), whereby tran-
sient episodes of ischemia and reperfusion (IR) pro-
tect the myocardium from prolonged IR injury, is the
most powerful cardioprotective therapy known and
has become the paradigm for cardioprotection (4).
The IPC infarct size-limiting effect is mediated
through the recruitment of pro-survival signaling
cascades at the early reperfusion phase, known as
the reperfusion injury salvage kinase pathway,
which encompasses the activation of 2 parallel ki-
nases: PI3K and ERK. The activation of this pathway
has been extrapolated to most cardioprotective in-
terventions, and is hence considered a unifying
signaling pattern for cardioprotection.
The reperfusion injury salvage kinase pathway was
ﬁrst described by our group in 2002 while assessing
the mechanisms underlying the cardioprotective ef-
fect induced by urocortin at reperfusion (5). At that
time, pro-apoptotic proteins were the object of study
to develop new targets against IR injury after the
realization that apoptosis may play an important role
in early reperfusion. The interest focused on 2 main
areas: 1) reducing cell death through the inhibition of
pro-apoptotic caspases (6); and 2) antagonizing the
apoptotic process through the activation of pro-
survival protein kinases, such as PI3K and ERK (7).
We believe that the results reported byWeil et al. (1)
further strengthen our understanding of cell death.
The increase in troponin levels following a short pro-
tocol of IR injury (IPC-like) has been justiﬁed by the
increased 6-fold regional apoptosis when compared
with the nonischemic tissue. The activation of theapoptotic process should be put alongside the well
recognized activation of pro-survival pathways
following a short protocol of IR injury. Therefore, it
seems that both pro-apoptotic and pro-survival path-
ways are activated after such a stimulus, maybe as a
counter-regulatory process. Despite it seeming con-
tradictory, we would speculate that this is exactly
what may happen. If the stimulus is left for longer,
apoptosis contributes alongside necrosis to the ﬁnal
infarct size (8), whereas if left only for a shorter period,
the IR injury actually leaves a “footprint,” i.e., a
memory in the form of activated pro-survival path-
ways to protect the heart when a prolonged injury
comes later. Maybe it is time to take apoptotic death
more seriously during early reperfusion!Xavier Rossello, MD
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